Victor Roeder
Occupational Vision · Ripon, WINPI 1417050246
Payments from drug & device makers
Across 24 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$247
- Alcon$74
- AbbVie$46
- Novartis$40
- Bausch & Lomb, A Division Of Bausch Health US, LLC$35
- ABB Con-cise Optical Group LLC$24
- plus $21 from 1 others
What the payments were for
- Food & beverage$485100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 12 | $247 |
| Alcon | 5 | $74 |
| AbbVie | 2 | $46 |
| Novartis | 2 | $40 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $35 |
| ABB Con-cise Optical Group LLC | 1 | $24 |
| Shire North American Group Inc | 1 | $21 |
How this compares
Too few occupational vision providers in Wisconsinto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 15 | $13,080 |
| XiidraLifitegrast | 11 | $10,786 |
| LumiganBimatoprost | 21 | $10,569 |
| Bimatoprost | 34 | $4,887 |
| Brimonidine Tartrate | 59 | $4,822 |
| Cyclosporine | 13 | $4,810 |
| Alphagan PBrimonidine Tartrate | 13 | $3,451 |
| Timolol Maleate | 48 | $2,572 |
| Loteprednol Etabonate | 14 | $1,947 |
| Latanoprost | 138 | $1,425 |
| Fluorometholone | 13 | $961 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $730 |
| Dorzolamide Hcl | 12 | $313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $46 | $27,10049 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $35 | $1,94714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few occupational vision providers in Wisconsinon file to place this against a meaningful peer group, so we don't.
Other occupational vision in Ripon
- Randall ZiethRipon$462
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.